Vinod Pullarkat

Feb 12, 2024 | onlinelibrary.wiley.com | Keith W Pratz |Brian A. Jonas |Vinod Pullarkat |Michael J. Thirman |Jacqueline Garcia |Hartmut Döhner | +9 more

1 INTRODUCTION Acute myeloid leukemia (AML) is a heterogenous neoplasm characterized by proliferation of immature myeloid cells in bone marrow and peripheral blood, leading to failure of normal hematopoiesis.1 AML is the most common acute leukemia in adults, with a median age at diagnosis of 68 years.

Sep 29, 2023 | onlinelibrary.wiley.com | Vaibhav Agrawal |Lindsey Murphy |Hoda Pourhassan |Vinod Pullarkat

What is the new aspect of your work? This is a comprehensive review of practical approaches to optimize outcomes with CD19-directed CAR-T cell therapy in adults with relapsed/refractory B-cell ALL. What is the central finding of your work? CAR-T cell therapy has demonstrated high response rates in adult R/R B-ALL and studies have identified factors predictive of response and toxicity, but relapse after CAR-T therapy remains a substantial concern.